Microbiome-based therapeutics for <i>Clostridioides difficile</i> infection: additive, subtractive, and modulatory strategies in modern clinical practice.
Microbiome-based therapies for CDI represent a promising shift towards ecological treatment strategies, but further clinical validation is needed.
Where it sits
this study against the rest of the mgf (mechano growth factor) corpusSummary and findings
This review explores microbiome-based therapeutic strategies for Clostridioides difficile infection, including additive, subtractive, and modulatory approaches. It synthesizes recent advances in basic, translational, and clinical research to provide a comprehensive understanding of these strategies. The review aims to guide future microbiome-targeted interventions beyond CDI.
Abstract
Microbiome-based therapeutics have rapidly evolved into a transformative field at the intersection of infectious diseases, microbial ecology, and precision medicine. <i>Clostridioides difficile</i> infection (CDI) represents the most extensively studied model, providing a framework for understanding microbiome-driven disease and ecological restoration. This review synthesizes three major therapeutic strategies, additive, subtractive, and modulatory, and integrates recent advances from basic, translational, and clinical research. Additive approaches, including fecal microbiota transplantation (FMT), live biotherapeutic products (LBPs), and defined microbial consortia, aim to restore microbial diversity and colonization resistance. Subtractive strategies selectively target <i>C. difficile</i> or its ecological advantages through targeted antibiotics, bacteriocins, bacteriophages, and CRISPR-based antimicrobials. Modulatory therapies reshape host-microbe and microbe-microbe interactions, targeting toxin activity, bile acid metabolism, and spore germination. Together, these approaches reflect a paradigm shift from pathogen-centered treatment toward ecological therapeutics targeting the dysbiotic niche underlying CDI persistence and recurrence. Understanding the similarities and differences between these strategies can help guide the design of future microbiome-targeted interventions and explore their potential beyond CDI across microbiome-mediated diseases.
Background
Clostridioides difficile infection (CDI) is a significant clinical challenge due to its persistence and recurrence, often linked to dysbiosis in the gut microbiome. Traditional treatments have focused on pathogen eradication, but recent advances suggest that targeting the microbiome itself may offer new therapeutic avenues. This review addresses the evolving landscape of microbiome-based therapies for CDI, highlighting their potential to transform treatment paradigms.
Methods
This is a review article synthesizing data from basic, translational, and clinical research on microbiome-based therapies for CDI. It categorizes therapeutic strategies into additive, subtractive, and modulatory approaches, discussing their mechanisms and potential applications. The review does not specify sample sizes, doses, or durations as it compiles findings from various studies.
Results
The review identifies three main strategies for microbiome-based CDI treatment: additive approaches like fecal microbiota transplantation, subtractive strategies targeting C. difficile, and modulatory therapies affecting host-microbe interactions. It highlights the potential of these strategies to restore microbial diversity and colonization resistance, reduce ecological advantages of C. difficile, and modulate toxin activity and bile acid metabolism.
Interpretation
This review provides a comprehensive overview of microbiome-based strategies for CDI, emphasizing a shift from traditional pathogen-focused treatments to ecological approaches. While the strategies show promise, their clinical significance remains to be fully established, as the review does not provide new experimental data. The integration of these strategies into clinical practice will require further validation through controlled trials.
Key findings
- Additive approaches include fecal microbiota transplantation, live biotherapeutic products, and defined microbial consortia.
- Subtractive strategies target C. difficile through targeted antibiotics, bacteriocins, bacteriophages, and CRISPR-based antimicrobials.
- Modulatory therapies focus on reshaping host-microbe and microbe-microbe interactions.
- The review emphasizes a shift from pathogen-centered treatment to ecological therapeutics.
- The strategies aim to address the dysbiotic niche underlying CDI persistence and recurrence.
Limitations
- No new experimental data provided
- Heterogeneous methodologies across included studies
- Lack of quantitative results
- Potential publication bias in reviewed studies